Insider Selling: Travere Therapeutics (NASDAQ:TVTX) Insider Sells 6,785 Shares of Stock

Key Points

• Insider sale: Director Elizabeth Reed sold 6,785 shares at an average price of $41.83 (total ~$283,817) under a pre-arranged Rule 10b5-1 plan to cover tax withholding, reducing her stake by 6.06% to 105,211 shares (≈$4.4M).
• Market reaction and trading: TVTX traded down to $40.95 on heavy volume (4.52M shares vs. a 2.20M average), with a 12-month range of $13.88–$43.31 and a market cap of about $3.78 billion.
• Primary catalyst: FDA full approval of Filspari for FSGS expanded Travere’s addressable market (~30,000 patients), sparked a ~37% share rally and prompted multiple analyst price-target upgrades, leaving the consensus rating at a "Moderate Buy" (average target ~$42.50).

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Elizabeth Reed sold 6,785 shares of the stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $41.83, for a total value of $283,816.55. Following the sale, the insider owned 105,211 shares in the company, valued at approximately $4,400,976.13. This trade represents a 6.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Travere Therapeutics Price Performance

Travere Therapeutics stock traded down $1.18 during mid-day trading on Wednesday, hitting $40.95. 4,521,912 shares of the company were exchanged, compared to its average volume of 2,203,580. Travere Therapeutics, Inc. has a 12-month low of $13.88 and a 12-month high of $43.31. The company has a market capitalization of $3.78 billion, a P/E ratio of -136.50 and a beta of 0.86. The business's 50 day simple moving average is $29.57 and its two-hundred day simple moving average is $31.37. The company has a debt-to-equity ratio of 2.71, a current ratio of 2.74 and a quick ratio of 2.70.

Analyst Ratings Changes

Several brokerages recently weighed in on TVTX. HC Wainwright reissued a "buy" rating and issued a $47.00 target price on shares of Travere Therapeutics in a research note on Tuesday. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Travere Therapeutics in a research note on Wednesday, January 21st. Wedbush lifted their price target on shares of Travere Therapeutics from $39.00 to $44.00 and gave the stock an "outperform" rating in a report on Tuesday. Canaccord Genuity Group boosted their price objective on shares of Travere Therapeutics from $47.00 to $56.00 and gave the company a "buy" rating in a research report on Tuesday. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Travere Therapeutics from $44.00 to $41.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 25th. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $42.50.

Hedge Funds Weigh In On Travere Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Rockefeller Capital Management L.P. lifted its position in Travere Therapeutics by 1,604.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 2,642 shares of the company's stock worth $101,000 after buying an additional 2,487 shares during the period. Mercer Global Advisors Inc. ADV purchased a new stake in Travere Therapeutics in the 4th quarter valued at about $278,000. Empowered Funds LLC purchased a new stake in Travere Therapeutics in the 4th quarter valued at about $115,000. KVP Capital Advisors LP acquired a new position in shares of Travere Therapeutics during the 4th quarter valued at about $3,477,000. Finally, XTX Topco Ltd increased its stake in shares of Travere Therapeutics by 475.0% during the 4th quarter. XTX Topco Ltd now owns 60,680 shares of the company's stock valued at $2,319,000 after acquiring an additional 50,127 shares during the last quarter.

Key Stories Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: FDA grants full approval for Filspari in focal segmental glomerulosclerosis (FSGS), expanding Travere’s rare kidney-disease franchise, adding an estimated ~30,000 patients to the U.S. addressable market and supporting multi-year revenue/earnings upside. Article Title
• Positive Sentiment: Market reacted strongly to the approval — shares jumped about ~37% on the news as investors priced in first-mover status, premium pricing potential and material volume-driven revenue growth for Filspari. Article Title
• Positive Sentiment: Multiple brokerages raised ratings/price targets following the approval (examples: Canaccord to $56, Guggenheim to $54, Piper Sandler to $49 overweight, Wedbush to $44, HC Wainwright reaffirmed buy). These upgrades signal increased analyst confidence in TAM expansion and revenue trajectory. Article Title
• Neutral Sentiment: Guggenheim issued a positive forecast note on TVTX that accompanies their price-target lift; this is incremental institutional support but not a guarantee of sustained momentum. Article Title
• Neutral Sentiment: Unusually high options activity and elevated trading volume were reported around the approval-related move, indicating heightened short-term speculation and positioning that can amplify volatility. Article Title
• Neutral Sentiment: Company-hosted commentary/transcripts and mainstream coverage (Seeking Alpha slides/transcript, MSN health reports) are providing more detail on label scope and commercial plans; useful for modeling uptake but not yet concrete sales figures. Article Title
• Negative Sentiment: Some analysts caution that recent earnings-estimate revision trends may limit further near-term upside despite the approval; elevated expectations and heavy short-term speculative flows raise the risk of a pullback or consolidation. Article Title

Travere Therapeutics Company Profile

Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.